DelveInsight’s, “Lipoxygenase Inhibitor (LOX Inhibitor) - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipoxygenase Inhibitor (LOX Inhibitor) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Lipoxygenase Inhibitor (LOX Inhibitor): Overview
Lipoxygenase (LOX) is a kind of rate-limiting enzyme in the process of arachidonic acid metabolism into leukotriene (LT) which mediates the occurrence of inflammation. The inhibition of LOX can reduce LT, thereby producing an anti-inflammatory effect. Lipoxygenase (LOX) can catalyze fatty acid to produce a number of active metabolic products that are involved in a lot of vital diseases. For instance, type 1 and type 2 diabetes (or both), cardiovascular diseases, hypertension, renal diseases, and neurological conditions such as Alzheimer's disease and Parkinson's disease.
LOX inhibitors are developed more slowly than COX inhibitors due to a lack of specific structure of LOXs. Additionally, as a result of the coexistence of LOXs in the same organism, LOX inhibitors should be designed seriously so as to achieve the targeting effect. In particular, another regulatory domain that is different from the two known domains of the C-terminal catalytic domain and the N-terminal β-barrel domain has been found, which will provide new ideas for the design of new LOX inhibitors.
The companies and academics are working to assess challenges and seek opportunities that could influence Lipoxygenase Inhibitor (LOX Inhibitor) R&D. The therapies under development are focused on novel approaches for Lipoxygenase Inhibitor (LOX Inhibitor).
This segment of the Lipoxygenase Inhibitor (LOX Inhibitor) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lipoxygenase Inhibitor (LOX Inhibitor) Emerging Drugs
Epeleuton: Afimmune
Epeleuton, previously named DS102, is 15-hydroxy eicosapentaenoic acid (15(S)-HEPE) ethyl ester, a second-generation synthetic n-3 fatty acid and derivative of an endogenous downstream metabolite of EPA. Epeleuton is a new chemical entity with additional therapeutic effects compared with other n-3 fatty acid. It acts as 5-Lipoxygenase Inhibitor (LOX Inhibitor) and is currently in Phase II of clinical trial for Alcoholic hepatitis, Chronic obstructive pulmonary disease, Diabetic neuropathies, Hypertriglyceridaemia, Idiopathic pulmonary fibrosis, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Type 2 diabetes mellitus.
Tipelukast: MediciNova
Tipelukast is being developed by MediciNova and is in Phase II forIdiopathic pulmonary fibrosis, Non-alcoholic steatohepatitis. It acts as 5-Lipoxygenase Inhibitor (LOX Inhibitor).
Further product details are provided in the report……..
This segment of the report provides insights about the different Lipoxygenase Inhibitor (LOX Inhibitor) drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the Lipoxygenase Inhibitor (LOX Inhibitor). The companies which have their Lipoxygenase Inhibitor (LOX Inhibitor) drug candidates in the most advanced stage, i.e. phase II include, Afimmune.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Lipoxygenase Inhibitor (LOX Inhibitor) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lipoxygenase Inhibitor (LOX Inhibitor) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lipoxygenase Inhibitor (LOX Inhibitor) drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Lipoxygenase Inhibitor (LOX Inhibitor): Overview
Pipeline Therapeutics
Therapeutic Assessment
Lipoxygenase Inhibitor (LOX Inhibitor) - DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Lipoxygenase Inhibitor (LOX Inhibitor) Collaboration Deals
Mid Stage Products (Phase II)
Epeleuton: Afimmune
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
PTC 857: BioElectron Technology
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
VLX 1005: Veralox Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Lipoxygenase Inhibitor (LOX Inhibitor) Key Companies
Lipoxygenase Inhibitor (LOX Inhibitor) Key Products
Lipoxygenase Inhibitor (LOX Inhibitor)- Unmet Needs
Lipoxygenase Inhibitor (LOX Inhibitor)- Market Drivers and Barriers
Lipoxygenase Inhibitor (LOX Inhibitor)- Future Perspectives and Conclusion
Lipoxygenase Inhibitor (LOX Inhibitor) Analyst Views
Lipoxygenase Inhibitor (LOX Inhibitor) Key Companies
Appendix
List of Table
Table 1: Total Products for Lipoxygenase Inhibitor (LOX Inhibitor)
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Lipoxygenase Inhibitor (LOX Inhibitor)
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Afimmune
• MediciNova
• Mariposa Health Limited
• MedWell Laboratories
• BioElectron Technology
• CSPC Ouyi Pharmaceutical
• Veralox Therapeutics
• Qurient Therapeutics
